Innovations in HR+/HER2- Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Introductions

Module 1: Mechanisms of Endocrine Resistance, Novel Therapeutic Mechanisms to Overcome Resistance, and Integrating Biomarker Testing Strategies in HR+/HER2- Metastatic Breast Cancer

Module 2: New Endocrine Therapies for Treating Endocrine-Resistant HR+/HER2- Breast Cancer

Module 3: Patient Case and Discussion

Module 4: Next-Generation Endocrine Therapies Using Novel Mechanisms to Overcome Endocrine Resistance in HR+/HER2- Breast Cancer